Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Item
http://www.wikidata.org/entity/Q43731443
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinomaEsophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation.Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancerActivation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancerIdentification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution.The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis.Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer modelSelection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's EsophagusTherapeutic approaches to gastroesophageal junction adenocarcinomasA systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
P2860

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Item
http://www.wikidata.org/entity/Q43731443
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Epidermal growth factor recept ...... d with worse clinical outcome.
@en
Epidermal growth factor recept ...... d with worse clinical outcome.
@nl
type
label
Epidermal growth factor recept ...... d with worse clinical outcome.
@en
Epidermal growth factor recept ...... d with worse clinical outcome.
@nl
prefLabel
Epidermal growth factor recept ...... d with worse clinical outcome.
@en
Epidermal growth factor recept ...... d with worse clinical outcome.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Epidermal growth factor recept ...... d with worse clinical outcome.
@en
P2093
P304
P31
P356
10.1016/J.HUMPATH.2012.08.005
P407
P433
P478
P50
P577
P698
P921